A molecular signature in blood identifies early Parkinsons disease

Molecular Neurodegeneration

Volumn 7, Issue 1, 2012, Pages

  Molochnikov, Leonid ^a   Rabey, Jose M ^a   Dobronevsky, Evgenya ^b   Bonucelli, Ubaldo ^c   Ceravolo, Roberto ^c   Frosini, Daniela ^c   Grünblatt, Edna ^d,e   Riederer, Peter ^e   Jacob, Christian ^e   Aharon Peretz, Judith ^f   Bashenko, Yulia ^g   Youdim, Moussa Bh ^g,h   Mandel, Silvia A ^g  

^a TEL AVIV UNIVERSITY   (Israel)

^b ASSAF HAROFEH MEDICAL CENTER   (Israel)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^f RAMBAM MEDICAL CENTER   (Israel)

^g TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^h Yonsei University   (South Korea)

Author keywords

Alzheimers disease; Blood Biomarker; CSF Biomarkers; E3 ubiquitin ligase; Early diagnosis; Heat shock protein Hsc 70; SCF; SKP1; Sporadic Parkinsons disease

Indexed keywords

19 S PROTEASOMAL PROTEIN; ALDEHYDE DEHYDROGENASE; HEAT SHOCK COGNATE PROTEIN 70; HUNTINGTIN INTERACTING PROTEIN 2; P19 S PHASE KINASE ASSOCIATED PROTEIN 1A; PROTEIN; PROTEIN KINASE P60; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC RISK; GENETIC TRANSCRIPTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PREDICTIVE VALUE; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SUBSTANTIA NIGRA;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; FEMALE; GENE EXPRESSION; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 84861651595     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-7-26     Document Type: Article

References (45)

1. Accuracy of clinical diagnosis of idiopathic Parkinsons disease: a clinico-pathological study of 100 cases. Hughes AJ, Daniel SE, Kilford L, Lees AJ, J Neurol Neurosurg Psychiatry 1992 55 181 184 10.1136/jnnp.55.3.181 1564476
2. Unified Parkinsons disease rating scale. Fahn S, Elton R, UPDRS Development Committee, In Recent Developments in Parkinsons Disease. Volume 2 Macmillan, New York, Fahn S, Marsden CD, Goldstein M, 1987 153 167 22704258
3. Evaluation of the Short Parkinsons Evaluation Scale: a new friendly scale for the evaluation of Parkinsons disease in clinical drug trials. Rabey JM, Bass H, Bonuccelli U, Brooks D, Klotz P, Korczyn AD, Kraus P, Martinez-Martin P, Morrish P, Van Sauten W, Van Hilten B, Clin Neuropharmacol 1997 20 322 337 10.1097/00002826-199708000-00004 9260730 (Pubitemid 27329734)
4. A short scale for the assessment of motor impairments and disabilities in Parkinsons disease: the SPES/SCOPA. Marinus J, Visser M, Stiggelbout AM, Rabey JM, Martinez-Martin P, Bonuccelli U, Kraus PH, van Hilten JJ, J Neurol Neurosurg Psychiatry 2004 75 388 395 10.1136/jnnp.2003.017509 14966153 (Pubitemid 38338767)
5. Parkinsonism: onset, progression and mortality. Hoehn MM, Yahr MD, Neurology 1967 17 427 442 10.1212/WNL.17.5.427 6067254
6. What features improve the accuracy of clinical diagnosis in Parkinsons disease: a clinicopathologic study. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ, Neurology 1992 42 1142 1146 10.1212/WNL.42.6.1142 1603339
7. Routine MRI for the differential diagnosis of Parkinsons disease, MSA, PSP, and CBD. Yekhlef F, Ballan G, Macia F, Delmer O, Sourgen C, Tison F, J Neural Transm 2003 110 151 169 10.1007/s00702-002-0785-5 12589575 (Pubitemid 36216498)
8. Differentiation of multiple system atrophy from idiopathic Parkinsons disease using proton magnetic resonance spectroscopy. Davie CA, Wenning GK, Barker GJ, Tofts PS, Kendall BE, Quinn N, McDonald WI, Marsden CD, Miller DH, Ann Neurol 1995 37 204 210 10.1002/ana.410370211 7847862
9. Phosphorus magnetic resonance spectroscopy in multiple system atrophy and Parkinsons disease. Barbiroli B, Martinelli P, Patuelli A, Lodi R, Iotti S, Cortelli P, Montagna P, Mov Disord 1999 14 430 435 10.1002/1531-8257(199905)14: 3<430::AID-MDS1007>3.0.CO;2-S 10348465 (Pubitemid 30011652)
10. The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Jankovic J, Rajput AH, McDermott MP, Perl DP, Arch Neurol 2000 57 369 372 10.1001/archneur.57.3.369 10714663 (Pubitemid 30140525)
11. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. Grunblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, Rechavi G, Li J, Ravid R, Roggendorf W, Riederer P, Youdim MB, J Neural Transm 2004 111 1543 1573 10.1007/s00702-004-0212-1 15455214 (Pubitemid 40068786)
12. Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. Hauser MA, Li YJ, Xu H, Noureddine MA, Shao YS, Gullans SR, Scherzer CR, Jensen RV, McLaurin AC, Gibson JR, et al. Arch Neurol 2005 62 917 921 10.1001/archneur.62.6.917 15956162 (Pubitemid 40973453)
13. Robust dysregulation of gene expression in substantia nigra and striatum in Parkinsons disease. Miller RM, Kiser GL, Kaysser-Kranich TM, Lockner RJ, Palaniappan C, Federoff HJ, Neurobiol Dis 2006 21 305 313 10.1016/j.nbd.2005.07. 010 16143538 (Pubitemid 43099854)
14. Whole genome expression profiling of the medial and lateral substantia nigra in Parkinsons disease. Moran LB, Duke DC, Deprez M, Dexter DT, Pearce RK, Graeber MB, Neurogenetics 2006 7 1 11 10.1007/s10048-005-0020-2 16344956 (Pubitemid 43327678)
15. Transcriptional analysis of multiple brain regions in Parkinsons disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. Zhang Y, James M, Middleton FA, Davis RL, Am J Med Genet B Neuropsychiatr Genet 2005 137 5 16 (Pubitemid 41076605)
16. Mendelian forms of Parkinsons disease. Gasser T, Biochim Biophys Acta 2009 1792 587 596 10.1016/j.bbadis.2008.12.007 19168133
17. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P, Chu C, Koepp DM, Elledge SJ, Pagano M, et al. Nature 2002 416 703 709 10.1038/416703a 11961546 (Pubitemid 34429140)
18. A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p. Feldman RM, Correll CC, Kaplan KB, Deshaies RJ, Cell 1997 91 221 230 10.1016/S0092-8674(00)80404-3 9346239 (Pubitemid 27456389)
19. CHIP: a quality-control E3 ligase collaborating with molecular chaperones. Murata S, Chiba T, Tanaka K, Int J Biochem Cell Biol 2003 35 572 578 10.1016/S1357-2725(02)00394-1 12672450 (Pubitemid 36369506)
20. Biological fluid biomarkers in neurodegenerative parkinsonism. Eller M, Williams DR, Nat Rev Neurol 2009 5 561 570 10.1038/nrneurol.2009.135 19724250
21. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinsons disease. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, et al. Brain 2010 133 713 726 10.1093/brain/awq008 20157014
22. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG, Lancet Neurol 2011 10 230 240 10.1016/S1474-4422(11)70014-X 21317042
23. Detection of elevated levels of {alpha}-synuclein oligomers in CSF from patients with Parkinson disease. Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T, Ishigami N, Tamaoka A, Nakagawa M, El-Agnaf OM, Neurology 2010 75 1766 1770 10.1212/WNL.0b013e3181fd613b 20962290
24. Plasma urate and risk of Parkinsons disease. Weisskopf MG, OReilly E, Chen H, Schwarzschild MA, Ascherio A, Am J Epidemiol 2007 166 561 567 10.1093/aje/kwm127 17584757 (Pubitemid 47283643)
25. Observations on serum uric acid levels and the risk of idiopathic Parkinsons disease. Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM, Am J Epidemiol 1996 144 480 484 10.1093/oxfordjournals.aje.a008954 8781463 (Pubitemid 26296131)
26. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A, Hyson C, Gorbold E, et al. Arch Neurol 2008 65 716 723 10.1001/archneur.2008.65.6.nct70003 18413464 (Pubitemid 351831449)
27. Molecular markers of early Parkinsons disease based on gene expression in blood. Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild MA, Schlossmacher MG, Hauser MA, Vance JM, et al. Proc Natl Acad Sci U S A 2007 104 955 960 10.1073/pnas.0610204104 17215369 (Pubitemid 46154718)
28. Evaluating the comparability of gene expression in blood and brain. Sullivan PF, Fan C, Perou CM, Am J Med Genet B Neuropsychiatr Genet 2006 141B 261 268 10.1002/ajmg.b.30272 16526044
29. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. Domenici E, Wille DR, Tozzi F, Prokopenko I, Miller S, McKeown A, Brittain C, Rujescu D, Giegling I, Turck CW, et al. PLoS One 2010 5 9166 10.1371/journal.pone.0009166 20161799
30. PGC-1alpha, a potential therapeutic target for early intervention in Parkinsons disease. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, et al. Sci Transl Med 2010 2 52ra73 10.1126/scitranslmed.3001059 20926834
31. SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinsons disease. Shehadeh LA, Yu K, Wang L, Guevara A, Singer C, Vance J, Papapetropoulos S, PLoS One 2010 5 9104 10.1371/journal.pone.0009104 20161708
32. Cerebrospinal fluid amyloid beta and tau in LRRK2 mutation carriers. Aasly JO, Shi M, Sossi V, Stewart T, Johansen KK, Wszolek ZK, Uitti RJ, Hasegawa K, Yokoyama T, Zabetian CP, et al. Neurology 2012 78 55 61 10.1212/WNL. 0b013e31823ed101 22170881
33. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA, J Lab Clin Med 2006 147 126 132 10.1016/j.lab.2005.10.005 16503242 (Pubitemid 43288168)
34. Human class I alcohol dehydrogenases catalyze the interconversion of alcohols and aldehydes in the metabolism of dopamine. Mardh G, Vallee BL, Biochemistry 1986 25 7279 7282 10.1021/bi00371a005 2432930 (Pubitemid 17220436)
35. Hepatic aldehyde dehydrogenases and lipid peroxidation. Hjelle JJ, Petersen DR, Pharmacol Biochem Behav 1983 18 Suppl 1 155 160 6634832
36. Ubiquitin-conjugating enzyme E2-25K increases aggregate formation and cell death in polyglutamine diseases. de Pril R, Fischer DF, Roos RA, van Leeuwen FW, Mol Cell Neurosci 2007 34 10 19 10.1016/j.mcn.2006.09.006 17092742 (Pubitemid 46026926)
37. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, ORourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, et al. Cell 2001 107 43 54 10.1016/S0092-8674(01)00507-4 11595184 (Pubitemid 32972036)
38. A sporadic parkinsons disease model via silencing of the ubiquitin-proteasome/E3-ligase component, SKP1A. Fishman-Jacob T, Reznichenko L, Youdim MB, Mandel SA, J Biol Chem 2009 284 47 32835 32845 10.1074/jbc.M109. 034223 19748892
39. ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinsons disease and in the ventral tegmental area in schizophrenia. Galter D, Buervenich S, Carmine A, Anvret M, Olson L, Neurobiol Dis 2003 14 637 647 10.1016/j.nbd.2003.09.001 14678778 (Pubitemid 37547970)
40. Gene and protein signatures in sporadic Parkinsons disease and a novel genetic model of PD. Mandel SA, Fishman T, Youdim MB, Parkinsonism Relat Disord 2007 13 Suppl 3 242 S247 18267243
41. Pilot study: peripheral biomarkers for diagnosing sporadic Parkinsons disease. Grunblatt E, Zehetmayer S, Jacob CP, Muller T, Jost WH, Riederer P, J Neural Transm 2010 117 12 1387 1393 10.1007/s00702-010-0509-1 21069393
42. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, et al. Ann Neurol 2010 69 570 580
43. Clinical diagnosis of Alzheimers disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM, Neurology 1984 34 939 944 10.1212/WNL.34.7.939 6610841 (Pubitemid 14076461)
44. Quantitative Real-Time PCR detection of TRPV1-4 gene expression in human leukocytes from healthy and hyposensitive subjects. Spinsanti G, Zannolli R, Panti C, et al. Mol Pain 2008 4 51 10.1186/1744-8069-4-51 18983665
45. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Vandesompele J, De Preter K, Pattyn F, et al. Genome Biol 2002 3 7 ESEARCH0034 12184808